GLYCOTOPE is a global leader in optimizing the glycosylation of biopharmaceuticals
GlycoExpress is one of the broadest platform technologies for the development and production of glycosylated proteins.
A clinical pipeline of 4 glycooptimized BioBetters and NBEs underlines GLYCOTOPE´s and its manufacturing arm GLYCOTOPE BIOTECHNOLOGY´s competence to contribute significant improvements to healthcare.
May 14 – 15, 2013
Stuttgart, Germany
May 31 – June 4, 2013
Chicago, USA
Berlin, Germany, June 14th, 2012 – GLYCOTOPE is due to successfully complete Phase I of its glycooptimized therapeutic antibody PankoMabTM and will move the compound to Phase II of clinical development in ovarian cancer with further indications planned to follow. …
Berlin, Germany, June 08th, 2012 – After successful completion of Phase I, the German biotech company GLYCOTOPE moves its glycooptimized therapeutic protein FSH-GEXTM into Phase II of clinical development in In-Vitro-Fertilisation. FSH-GEXTM is based on Glycotope’s unique and proprietary GlycoExpressTM …